Delek US (NYSE: DK) CEO sells 50,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

Delek US Holdings, Inc. President & CEO Avigal Soreq reported selling a total of 50,000 shares of common stock on March 3, 2026 in three open-market transactions. The weighted average sale prices were $41.71, $40.90, and $39.85 per share, each reflecting multiple trades within stated price ranges. These transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025. After these sales, Soreq directly holds 251,678 shares of Delek US common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Soreq Avigal

(Last) (First) (Middle)

310 SEVEN SPRINGS WAY

SUITE 500

(Street)

BRENTWOOD TN 37027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Delek US Holdings, Inc. [ DK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		S(1)		13,768	D	$41.71(2)	287,910	D
Common Stock	03/03/2026		S(1)		34,332	D	$40.9(3)	253,578	D
Common Stock	03/03/2026		S(1)		1,900	D	$39.85(4)	251,678	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a 10b5-1 plan adopted on December 3, 2025, and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

2. The price reflects the weighted average sale price of multiple transactions ranging from a low sale price of $41.36 per share to a high sale price of $42.35 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each sale price.

3. The price reflects the weighted average sale price of multiple transactions ranging from a low sale price of $40.34 per share to a high sale price of $41.34 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each sale price.

4. The price reflects the weighted average sale price of multiple transactions ranging from a low sale price of $39.70 per share to a high sale price of $40.33 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each sale price.

Remarks:

	/s/ Misty Lavender, Attorney in Fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Delek US (DK) CEO Avigal Soreq report?

Avigal Soreq reported selling 50,000 Delek US common shares in three open-market transactions on March 3, 2026. The trades used weighted average prices of $41.71, $40.90, and $39.85 per share under a pre-arranged Rule 10b5-1 trading plan.

At what prices did the Delek US (DK) CEO sell his shares?

The CEO’s reported sales used weighted average prices of $41.71, $40.90, and $39.85 per share. Each figure reflects multiple trades within specified intraday ranges, with full price-by-price details available upon written request to the company, the SEC, or a security holder.

How many Delek US (DK) shares does the CEO still own after these sales?

After the reported transactions, Avigal Soreq directly owns 251,678 shares of Delek US common stock. The Form 4 shows this post-transaction balance following the final open-market sale on March 3, 2026 executed under his Rule 10b5-1 trading plan.

Were the Delek US (DK) CEO share sales under a Rule 10b5-1 plan?

Yes. The filing states the transactions were made under a Rule 10b5-1 trading plan adopted on December 3, 2025. Such plans allow pre-scheduled trades, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) regarding insider trading regulations.

How many total Delek US (DK) shares did the CEO sell on March 3, 2026?

The Form 4 shows Avigal Soreq sold an aggregate 50,000 shares of Delek US common stock on March 3, 2026. These were executed as three separate open-market sale transactions, each reported with its own share amount and weighted average sale price.